Radiation Oncology

I have a pair of patients with MRI+ and biopsy+ disease who have staging PSMA PET/CT that do not show disease within the prostate (or anywhere else).&...

2 Answers available

How do you manage hot flashes in men with prostate cancer on androgen deprivation therapy?

16 Answers available

Can you/do you use an androgen receptor blocker alone in patients with metastatic hormone-sensitive prostate cancer who cannot tolerate GnRH-directed therapy?

7 Answers available

How would you treat margin positive, node positive (pN+) prostate cancer with detectable post-op PSA but negative PSMA-PET after radical perineal prostatectomy?

How does margin positive influence your decision?

1 Answer available

How do you manage dry eye related to Pluvicto Lu-177?

2 Answers available

How do you sequence Ra-223 and Lu-177 in patients with mCRPC with predominantly bony disease?

Do you preferentially use Ra-223 first given the RALU study?

1 Answer available

Is there a role for radiotherapy to the primary in high volume metastatic prostate cancer with well controlled disease on ADT?

1 Answer available

How do you reconcile discrepancies in clinical prostate cancer staging with AJCC and NCCN?

In particular, in the modern era of multi-parametric prostate MRI and PSMA-PET, certain findings such as EPE, SVI, or pelvic lymphadenopathy may be no...

7 Answers available

Do you cover the sacral foramen when treating pelvic lymph nodes for prostate cancer?

2 Answers available

For what duration should abiraterone be used in a patient with biochemical and pelvic node recurrence (N1M0) who had prior definitive therapy with either RP or RT?

Do you feel comfortable stopped abiraterone after 2 years?

2 Answers available

Is there a role for prostate cancer lesion boost with EBRT in the setting of combination EBRT+ brachytherapy?

In the setting of EBRT alone, a "FLAME"-style boost may increase bPFS. Does anyone have experience with increasing the EBRT dose in combination EBRT+L...

1 Answer available

Has use of PSMA PETCT revealed increased local failures than previously known after definitive prostate EBRT with biochemical failure?

3 Answers available

How do you treat localized prostate cancer with neuroendocrine differentiation?

4 Answers available

How would you treat high risk prostate cancer in a patient with autonomic bladder dysfunction?

He cannot sense bladder fullness but has no incontinence. Intermittently he urinates by increasing intra-abdominal pressure resulting in a good stream...

1 Answer available

Do you utilize genetic testing to guide ADT for men receiving XRT for intermediate or high risk prostate cancer?

For example do you use Prolaris, or other genetic tests to guide ADT decision making?

5 Answers available

Would you ever consider focal brachytherapy treatment in a patient who have in-prostate recurrences after RT?

Assume recurrence is biopsy proven. Would you ever consider focal vs whole gland brachytherapy?

5 Answers available

Do you always obtain PSMA PET as initial staging for high risk and very high risk localized prostate cancer patients?

6 Answers available

Are there reasons to not use prostate SBRT when treating the prostate +\- proximal SV?

2 Answers available

Do you have recommendations after prostate RT for patients who want to conceive?

Patients in their later 40s with favorable intermediate-risk prostate cancer s/p 7000cGy/28 EBRT only.

1 Answer available

Would you consider adding abiraterone to ADT and salvage RT in a prostate cancer patient with pN1 disease at radical prostatectomy?

24 months ADT + abiraterone + definitive RT is indicated for cN1 disease but not for pN1 disease per NCCN. Can the data be extrapolated to this popula...

1 Answer available

In a patient with very high risk prostate cancer opting for prostatectomy, when, if ever, do you recommend neoadjuvant ADT?

4 Answers available

How aggressive would you be in irradiating asymptomatic bone metastases in a patient with metastatic prostate cancer?

Notably, the patient presented with renal failure due to ureteral obstruction and hydronephrosis, receives hemodialysis, and has limited systemic opti...

4 Answers available

What isotope and dose do you prefer for prostate brachytherapy monotherapy?

4 Answers available

What factors do you take into account when deciding to offer SpaceOAR to patients with prostate cancer planning to undergo radiation therapy?

For example: radiation fractionation schedule, modality (proton, MRI linac, cyberknife, etc), risk categorization, prostate size, history of IBS, hist...

6 Answers available

What is the optimal duration of ADT for unfavorable intermediate risk or high risk localized prostate cancer treated with SBRT instead of conventionally fractionated or hypofractionated RT?

Do you also give neoadjuvant, concurrent, and adjuvant ADT in the same manner as for non-SBRT EBRT?

5 Answers available

How would you treat synchronous high-risk prostate and rectal adenocarcinomas in an elderly man where the rectal cancer was resected secondary to obstruction (T3N0)?

How would you sequence therapy, and what dose and volumes would you use for radiation? Prostate cancer is localized, Gleason 4+3, PSA 65.

2 Answers available

How do you interpret PSMA/PET with focal prostate activity after XRT currently on ADT with stable PSA?

Pretreatment PSA 25.3 with Gleason 4+3=7 and MRI suspicious for ECE. Eight months after pelvic nodal and prostate XRT to 79 Gy, PSA is 5.02 (down from...

1 Answer available

What dose constraint(s) would you use for a patient with a pelvic kidney transplant getting pelvic RT?

1 Answer available

Would you treat the prostate in a patient with widely metastatic disease who has CR to all metastatic sites after systemic therapy or ADT?

2 Answers available

Do you recommend prostate RT for patients with metastatic (M1) disease?

A recent NCBD analysis (Rusthoven et al., PMID 27325855) suggests that the addition of prostate RT significantly improves survival compared to AD...

8 Answers available

Do you ever initiate on degarelix and then switch to leuprolide for patients with prostate cancer and cardiac risk factors receiving ADT?

If so, how long are they on degarelix before the switch?

2 Answers available

How would you treat pelvic node recurrence after prior RP and adjuvant XRT prostate bed only?

Would you recommend elective nodal radiation and sequential boost to the node? What dose? Would you recommend treatment similar to OLIGOPELVIS-GETUG P...

4 Answers available

What combination of clinical and pathologic features would lead you to be comfortable recommending active surveillance in a Gleason 7 prostate cancer patient?

3 Answers available

How soon after SpaceOAR placement can radiation planning CT be performed?

7 Answers available

How should the results of molecular/genetic tests for prostate cancer, be utilized in the post-prostatectomy setting?

There is a recent publication that nicely summarizes the molecular/genetic tests for prostate cancer (Ross et al., PMID 26123120). What should be done...

2 Answers available

What systemic therapy do you recommend for prostate cancer pelvic nodal recurrence on PSMA PET-CT after prostatectomy and salvage radiation?

If ADT +/- ARPI + RT, what duration of systemic therapy do you recommend?

1 Answer available

Would you omit pelvic XRT in a high risk prostate patient with negative nodal uptake on PSMA but has risk of nodal involvement >15% by nomogram?

4 Answers available

What is the recommended length for ADT in the setting of N1 disease receiving definitive radiation?

1 Answer available

How do you approach a patient with prostate cancer with sclerotic/lytic lesions found on a CT scan but not seen on a bone scan or PET-PSMA?

Would you consider these as metastatic sites? Would you biopsy to confirm?

3 Answers available

Do you hold anticoagulation prior to LDR or HDR prostate brachytherapy?

If so, when do you resume?

1 Answer available

Do you change your monitoring strategy for a high risk prostate cancer after XRT if the initial PSAs have never been very high?

4 Answers available

Does recent COVID-19 infection result in elevated PSA?

1 Answer available

How do you approach management of a patient with intermediate risk prostate cancer treated upfront with HIFU and intermittent ADT who is later found to have rising PSA and biopsy-proven prostate-confined recurrence?

Is this considered salvage or definitive since HIFU is not standard of care? Does receipt of upfront HIFU impact ability to perform stand...

3 Answers available

Has the recent presentation of RADICALS-HD changed your ADT duration recommendations for patients receiving post operative radiation therapy for prostate cancer after radical prostatectomy?

2 Answers available

Would you use abiraterone or docetaxel in addition to ADT and radiotherapy for patients with very high risk, node-negative prostate cancer?

2 Answers available

In asymptomatic patients with unfavorable intermediate risk prostate cancer and a PSA <10, how helpful/reliable and clinically useful is bone imaging?

2 Answers available

Which imaging modality do you prefer when monitoring disease status for patients with prostate cancer undergoing 177-Lu PSMA treatment?

PSMA PET vs Conventional imaging vs combined imaging?

4 Answers available

Would you recommend definitive XRT with extensive lymph node involvement of prostate cancer?

Is there an extent of nodal involvement in prostate cancer above which you would not offer definitive XRT? With PSMA/PET we see some patients with inc...

1 Answer available

How do you approach a patient with a radiographically proven recurrence in the prostate bed after prostatectomy?

If a patient who has undergone radical prostatectomy many years previously presents with biochemical failure and is found to have a nodule in the pros...

3 Answers available

In a patient with otherwise low-risk prostate cancer, does presence of a small component of Grade Group 3 disease up-stage to unfavorable intermediate?

How would you treat such a patient?

3 Answers available

Are you comfortable combining relugolix with enzalutamide or abiraterone?

Current NCCN guidelines recommended not combining relugolix with these agents until more data is available. Any drug interaction concerns or ot...

1 Answer available

What references do you use for multi-parametric MRI delineation of the GTV in prostate cancer for prostate nodule?

Specifically, in the TZ and PZ? What references do use for prostate nodule boost as done in FLAME trial? Hypointensities are contoured on T2W M...

2 Answers available

Do you recommend a waiting period to conceive after prostate radiation?

1 Answer available

What treatment would you offer for a patient with prior primary prostate radiation, with a biochemical progression to PSA >1.0 and negative PSMA scan?

3 Answers available

For a patient with localized high risk prostate cancer with high risk Decipher score receiving ADT and abiraterone, is there any value of continuing ADT and abiraterone beyond two years?

2 Answers available

How does a diffusely positive PSMA in the prostate affect treatment planning in a patient with MRI and biopsy showing only one area of disease?

Would you consider repeating a biopsy?

1 Answer available

Do you boost involved mesorectal nodes in node positive prostate cancer?

How high would you try to boost those involved nodes if they are in a favorable location with respect to his rectum and small bowel?

4 Answers available

How long do you wait to start adjuvant radiation after prostatectomy?

2 Answers available

Would you consider SBRT for node negative small cell carcinoma of the prostate?

2 Answers available

What duration of ADT + abiraterone do you recommend prior to initiation of HDR brachytherapy followed by EBRT for very high risk localized cT3bN0 prostate cancer?

1 Answer available

How do you approach rising PSA many years after prostatectomy with negative PSMA PET?

4 Answers available

Would you treat the pelvis electively while treating the prostate in a setting of low volume metastatic prostate cancer?

2 Answers available

How would you manage a patient with PSA relapse 10 years after salvage radiotherapy with PSA doubling time<6 months?

Would you treat with ADT if no metastatic disease? Does absolute PSA (e.g. PSA<2) inform decision?

1 Answer available

Do you hold ADT prior to biopsy of possible prostate cancer metastatic disease?

Does ADT affect the results of a biopsy?

1 Answer available

How would you work up a patient with prostate cancer with bone scan suspicious for metastatic disease and a negative PSMA PET/CT?

Additional imaging of the potential lesions, biopsy or assume negative given normal PSMA PET/CT.

7 Answers available

How does prior prostate artery embolization impact your treatment recommendations for prostate cancer?

1 Answer available

For unfavorable intermediate prostate cancer in elderly patients, would you consider radiation without ADT?

2 Answers available

How would you manage a low risk patient with a negative fusion prostate lesion by biopsy but MRI shows apparent advanced disease?

Do you allow this finding to change your management, or ignore it, as the "lesion" was not malignant?

3 Answers available

How would you treat node positive (pN+) prostate cancer with undetectable post-op PSA after radical prostatectomy and pelvic LND?

Would you offer adjuvant radiation? (Dose? Target?) vs Salvage? Would you add ADT? Would you add abiraterone? Would the number of lymph nodes involv...

3 Answers available

How do you treat a rectoprostatic fistula after prostate SBRT?

2 Answers available

How do you fractionate prostate cancer where there was rectal wall infiltration by hydrogel after healing?

3 Answers available

Would you treat a patient with metastatic castration resistant prostate cancer and prior treatment with Ra-223 with Lu-117-PSMA-617 therapy?

Is prior Ra-223 a contraindication for treatment?

1 Answer available

What can prostate patients do for sexual function while on ADT?

4 Answers available

Would you ever recommend testosterone replacement for men with incomplete T recovery after ADT for prostate cancer?

Patient has ED unresponsive to cialis/viagra; would you recommend testosterone replacement therapy?

5 Answers available

How does urinary obstruction impact your choice of therapy for metastatic or locally advanced prostate cancer?

1 Answer available

In high or very high risk prostate cancer, do you utilize combined androgen blockade in patients receiving definitive RT?

Do you have a preference for bicalutamide? Can abiraterone be used instead?

6 Answers available

At what PSA level would you consider restaging a patient who was treated with ADT and radiation and had undetectable PSA?

At what PSA would you become suspicious for biochemical recurrence and pursue restaging? Is there a threshold value? What imaging modality would you ...

2 Answers available

When would you use PSMA PET over conventional imaging for prostate cancer?

Would you use it for initial staging or at time of biochemical recurrence?

2 Answers available

How would you manage prostate cancer in a patient who received prior chemoradiation followed by an APR for rectal cancer?

If a patient is not a surgical candidate, what it the most appropriate treatment?

2 Answers available

How do PSMA PET positive nodes change your treatment recommendations after RP?

Would you consider boosting the nodes? What dose? Would this change your recommendation for length of ADT?

2 Answers available

How do you typically prescribe dose to a PTV for standard IMRT plans?

3 Answers available

What are your top takeaways from ASCO GU 2022?

6 Answers available

Do you consider ADT intensification with enzalutamide or abiraterone in patients receiving adjuvant radiation with ADT?

Are there clinical features (post-op PSA, Decipher score, pN+, pT3, etc) that would inform your decision?

2 Answers available

Would you offer hypofractionation to a patient in the salvage/adjuvant post-prostatectomy setting outside of a clinical trial?

Given GU003 presented at ASTRO 2021- how does this impact your recommendations for adjuvant and salvage prostate RT?

4 Answers available

Do you hold ADT before work up for prostate cancer when ordering advanced imaging such as PSMA PET?

Do you worry about false negatives on PET, CT, MRI if ADT is started before the scan? Scheduling scans can sometimes book 2-4 weeks out.

2 Answers available

For men with intermediate or high-risk prostate cancer, can an SBRT boost be used in place of a brachytherapy boost after EBRT?

3 Answers available

Do you account for dose from previous Lu-177 treatment for definitive prostate cancer treatment?

Per lutathera information, a patient who had previous treatment for describes an estimated radiation absorbed dose of 12.8 Gy to the bladder. Would yo...

1 Answer available

How would you treat a patient with Gleason 8 or 9 prostate cancer, pretreatment PSA 15-24, with retroperitoneal adenopathy?

Is there a role of EBRT to the prostate with extended fields to cover the retroperitoneal nodes plus ADT (definitive therapy) or would you treat as ca...

4 Answers available

Is there an absolute PSA level above which you would not recommend a radical prostatectomy for newly diagnosed prostate cancer despite the absence of metastatic disease with advanced imaging?

Are there other high or very high risk features that would also contribute to your decision making?

1 Answer available

Would you recommend surgery or radiation for newly diagnosed localized prostate cancer diagnosed on a urethral lesion biopsy?

GS 4+4. PSA low (1-2). CT and bone scan negative for lymphadenopathy or metastatic disease. Prostate MRI pending.

2 Answers available

Will you consider adding an AR targeted agent to ADT for a patient thought to have isolated pelvic nodal recurrence of prostate CA if next generation imaging reveals additional non-regional disease not seen on conventional imaging?

Patient previously had prostatectomy and salvage RT

1 Answer available

What is the best approach to organ confined squamous cell cancer of the prostate?

Would you recommend surgery first or neoadjuvant therapy such as concurrent cisplatin/RT or another regimen?

1 Answer available

Which patients with mCRPC on ADT + advanced anti-AR do you treat with bisphosphonates or denosumab?

Did you change your practice given the SRE results in the control arm of EORTC 1333 at ASCO 2021? When using bisphosphonates or denosumab, what dosin...

2 Answers available

How exactly would you utilize ADT via leuprolide or bicalutamide with salvage RT post prostatectomy with PSA >0.5?

2 Answers available

How would you manage a patient with favorable intermediate prostate cancer patient who obtains a high Decipher test score at the end of their RT course?

Would you consider adding ADT?

1 Answer available

Would you treat pelvic lymph nodes in your salvage prostate patient after RP without adverse features due to a limited/no pelvic lymph node sampling?

For the purpose of this question, please assume an initially undetectable post-prostatectomy PSA, no presence of positive margins, extracapsular exten...

1 Answer available

When do you use a rectal spacer in combination with radiotherapy for prostate cancer?

Are there certain situations where a hydrogel spacer is most useful based on treatment modality (SBRT, protons, brachy, etc) or other factors?

2 Answers available

How would you sequence 177LU-PSMA-617 with current therapies for men with mCRPC?

2 Answers available

Would you consider radical prostatectomy for a young male with unfavorable intermediate risk cT3a prostate cancer and PSMA PET concerning for regional lymph nodes involvement but negative conventional imaging?

Gleason 4+3=7 and PSA 4

3 Answers available

Do you consider tertiary grade pattern, LVI or PNI on prostatectomy specimens as adverse features to recommend EBRT and ADT for patients with unfavorable intermediate prostate CA after prostatectomy with undetectable PSA?

Are there other adverse features aside from seminal vesicle invasion, positive margins, or extraprostatic extension that you consider?

1 Answer available

For persistent PSA elevation after prostatectomy, would you recommend salvage radiation if pathologically negative nodes, but regional and non-regional lymphadenopathy on PSMA PET?

Specifically, would you offer salvage radiation to a patient who underwent a prostatectomy with PLND and had a post-op PSA of 12 with pathology reveal...

2 Answers available

Would you consider adding abiraterone or docetaxel in patients with high risk prostate cancer whose PSA does not become undetectable after ADT and radiotherapy with castrate level testosterone?

4 Answers available

What duration of ADT do you recommend for a patient with locally treated prostate cancer who undergoes metastasis-directed radiation therapy to a single oligometastatic bone lesion?

Would you add abiraterone or enzalutamide?

5 Answers available

How would you manage a male with a prior history of localized prostate cancer s/p radiation to prostate only (two years ago), who now presents with a T1N0 squamous cell carcinoma of the anus?

Would your management change if the prostate and lymph nodes were treated with radiation two years ago?

2 Answers available

How would you manage a patient with localized prostate cancer treated with radical prostatectomy and found to have a single involved pelvic lymph node on final pathology and a detectable postoperative PSA?

2 Answers available

Would you give abiraterone in the post-prostatectomy setting to patients with positive nodes detected at surgery?

Is there data and FDA approval for this indication? What about for nodal failure after radiation?

1 Answer available

How would you deliver salvage prostate bed radiation in a patient with a neobladder?

What dose constraint would you use for the neobladder? Small bowel constraint of 54Gy? Or would you recommend observation or ADT alone or low dose RT ...

1 Answer available

Would you treat unfavorable intermediate risk prostate cancer in the setting of recently resected NSCLC?

How would a much higher risk cancer affect decision making? How would you treat him?

3 Answers available

For recurrent prostate cancer after definitive radiation, how do you guide patients between the various salvage options vs ADT?

1 Answer available

What is the optimal duration of ADT for cN1 disease with EBRT?

3 Answers available

Would you offer PA nodal XRT in a patient with rising PSA and multiple PET positive nodes after previous prostate XRT treatment that is otherwise locally controlled?

For instance, if the fluclicovine scan shows a few small avid nodes not only in the pelvis but extending to the paraaortic region, would you treat the...

2 Answers available

Would you offer salvage radiation for biochemically recurrent prostate cancer with a transplanted pelvic kidney?

Will your recommendation change if there is suspicious/confirmed locally recurrent nodule in the prostate bed?

3 Answers available

Would you offer modest hypofractionation (e.g. 70 Gy/28 fractions) to a patient with intermediate risk prostate cancer and celiac disease?

1 Answer available

How do you manage androgen deprivation in a patient with oligometastatic prostate cancer in which the primary and all known metastatic sites have been treated with curative intent radiation and PSA remains undetectable?

How long would you continue androgen deprivation after radiation?

2 Answers available

Would you recommend Radium-223 for extensive bone disease in a prostate cancer patient with adenopathy >3cm?

Per the ALSYMPCA study, they excluded patients with > 3cm lymphadenopathy. Patient is currently on enzalutamide and leuprolide and refuses docetaxe...

1 Answer available

Is there a role for docetaxel for men with high risk prostate cancer receiving radiation and androgen deprivation therapy?

Does the STAMPEDE trial, showing a survival benefit with the addition of docetaxel to standard treatment, change the standard of care for high risk, n...

4 Answers available

Do you deliver prostate SBRT every other day or consecutively?

Is there a benefit to one fractionation schedule v. the other?

3 Answers available

How would you approach an isolated prostate recurrence of high-risk prostate cancer following definitive EBRT?

4 Answers available

Is it appropriate to use photon energies above 15 MV for prostate SBRT?

Do we need to really worry about neutron contamination?

7 Answers available

In a patient who requires prostate cytoreduction prior to EBRT or brachytherapy, do you include a 5-alpha reductase inhibitor in your ADT regimen?

1 Answer available

How would the presence of active rheumatoid arthritis on methotrexate impact your choice of fractionation for a patient with prostate cancer?

1 Answer available

How do you treat newly diagnosed low volume metastatic hormone sensitive prostate cancer in light of new data from STAMPEDE presented at ESMO 2018?

Abstract LBA5_PR ‘Radiotherapy (RT) to the primary tumour for men with newly-diagnosed metastatic prostate cancer (PCA): survival results from S...

1 Answer available

How do you determine dose for prostate SBRT?

Is there a dose response relationship, as suggested in the phase I MSKCC dose escalation study presented at ASTRO 2017?

2 Answers available

What dose and fractionation is safe to use for palliation of a large pelvic mass several years after definitive prostate brachytherapy?

1 Answer available

What is the optimal duration of ADT in high-risk prostate cancer treated with RT+ADT?

Based on the updated results of the PCS IV trial is 18 months of ADT the new standard of care for men with high-risk prostate cancer treated with...

4 Answers available

Is ADT alone appropriate for high risk prostate cancer patients without evidence of metastasis and limited life expectancy?

Is there data to support this practice, which appears in the NCCN guidelines?

1 Answer available

For what patient groups (if any) do you routinely recommend screening colonoscopy prior to radiation for prostate cancer?

3 Answers available

When do you offer salvage prostate bed RT to patients who have a biochemical recurrence >5 years after RP?

In the case of patients many years out from RP who have a slowly rising PSA, do you offer salvage RT while the PSA is still very low or follow the PSA...

1 Answer available

How do you manage musculoskeletal pain in men receiving androgen deprivation therapy for non-metastatic prostate cancer?

In patients with new bone pain and without any evidence of bone metastases receiving GnRH agonists, how do you manage pain symptoms?

1 Answer available

If a patient with non-metastatic prostate cancer is found to have a BRCA mutation, should this influence treatment recommendations for local therapy?

2 Answers available

What is your approach to patients with locally recurrent prostate cancer following cryotherapy or HIFU?

With biopsy-proven, negative systemic restaging disease, what dose and fractionation is appropriate if treating with IMRT? Should ADT generally b...

1 Answer available

Does a transitional zone vs. peripheral zone location of low risk prostate cancer affect your recommendation for active surveillance?

1 Answer available

Do you treat pelvic lymph nodes in patients with high-risk prostate cancer who refuse ADT?

Would you consider this an indication to treat lymph nodes, if you would typically not do so?

2 Answers available

Should definitive radiotherapy and ADT be offered to patients with PSA > 100 who have no evidence of metastatic disease?

Is there an upper limit to offer definitive RT? Is it possible to have a PSA of 100-500 and still have only local disease?

6 Answers available

How do you approach isolated recurrence in a para-aortic lymph node following definitive radiation for localized prostate cancer?

Is there a role for salvage LN dissection or salvage RT to the node? And is there a role for systemic therapy (ADT or chemotherapy) in addition? If yo...

1 Answer available

What imaging workup should be completed in patients with a detectable PSA following prostatectomy?

Should the workup change with the PSA level (for example, >2 vs <2 ng/ml post-op PSA)? Is there a PSA level for which salvage radiotherapy...

2 Answers available

Do you counsel patients on the risk of dementia following androgen deprivation therapy for prostate cancer?

Two retrospective studies from Stanford showed that patients who received ADT had an increased risk of dementia and Alzheimer's. Is this finding ...

3 Answers available

When do you initiate androgen deprivation therapy for biochemical relapse of prostate cancer following primary therapy?

Do you use a PSA threshold, PSA doubling time, or only evidence of metastatic disease to trigger ADT? For those without rapid doubling time, do you ev...

1 Answer available

Do you treat with high-dose radiation alone (without ADT) for favorable intermediate risk prostate cancer?

If so, what criteria do you use to guide your decision?

3 Answers available

How do you define PSA progression after salvage or adjuvant prostate fossa radiotherapy?

In the recent 10 year update of the ARO (adjuvant pelvic RT versus observation) trial, their definition of PSA failure was 2 successive rise...

3 Answers available

What duration of androgen deprivation therapy do you use for patients with pN+ prostate cancer undergoing upfront adjuvant RT after a radical prostatectomy and pelvic lymph node dissection?

Do other factors (i.e. Gleason score, pretreatment PSA, or pT stage) affect your decision?

2 Answers available

What criteria do you use when considering treating the pelvic nodes in a salvage prostatectomy case versus covering only the postoperative bed?

Would a specific Gleason score, age, pathological feature, or PSA be an indication for covering the pelvic nodes? Would giving concurrent ADT affect y...

3 Answers available

Which, if any, aspects of your management of prostate cancer differ in your African-American patients versus those of other racial/ethnic backgrounds?

Given recent advancements in the understanding of biological differences in prostate cancer patients of African vs. other ancestry, does your manageme...

1 Answer available

At what PSA do you initiate ADT for a biochemical recurrence after prostate radiotherapy (adjuvant, salvage, or definitive)?

Does PSADT play a factor in your decision-making? If so, how specifically? I've tended to wait until the PSA is 10-15, re-image, and then begin...

1 Answer available

For patients eligible for and considering active surveillance for low-risk prostate cancer, do you routinely use tests for molecular risk stratification?

Are there specific subsets for whom these results should change management?

1 Answer available

Which PET imaging modality, if any, is preferred to work up possible nodal involvement or local recurrence in prostate cancer?

In situations where there is a significant risk of either local or nodal persistence/recurrence post prostatectomy with a rising PSA, or nodal involve...

1 Answer available

When should intermittent androgen deprivation vs continuous androgen deprivation be used for the treatment of prostate cancer?

In a patient with node positive disease, treated definitively with radiation, should continuous or intermittent ADT be administered? If a patien...

1 Answer available

When does a rising PSA after prostatectomy indicate growth just of normal prostate?

Guidelines dont seem to account for this possibility. Could it just be normal prostate tissue growing back that is leading to PSA, why just assume it ...

1 Answer available

How do you manage high risk prostate cancer patients with well controlled Crohn's disease?

Do you offer RT if the patient is well controlled on medications?

2 Answers available

What are the most common errors that can be made when performing prostate SBRT?

In starting prostate SBRT at an instutution, what are issues with the treatment that one should pay special attention to?

2 Answers available

At what point would Radium-223 dicholoride treatment be the best management for a patient with established metastatic prostate cancer with an elevated PSA and symptomatic bone pain with corresponding bone lesions on imaging?

1 Answer available

For biochemical failure following prostatectomy, is there a PSA value that would be considered too high to offer local salvage radiotherapy?

On what other factors should be considered in making a treatment recommendation for salvage radiation therapy?

3 Answers available

When should SBRT be offered to oligometastatic bone disease in a patient with prostate cancer?

What factors should be considered with offering SBRT to oligometastatic bone disease in prostate cancer patients? Should this been done off of a proto...

2 Answers available

At what PSA do you start calculating doubling time post-prostatectomy?

With ultra-sensitive PSA, it's unclear to me whether a doubling from 0.01 to 0.02 or 0.02 to 0.04 is significant. Is there a certain value that you wo...

1 Answer available

How long should the duration of hormones be in post-prostatectomy patients receiving salvage RT?

If a patient is deemed high risk enough to require hormones with RT in the salvage setting, how long would you maintain them on ADT? Would you extrapo...

2 Answers available

Do you forgo adjuvant radiotherapy for men with pT3 prostate cancer who have significant urinary incontinence?

Would you favor only offering salvage therapy if the PSA rises?

5 Answers available

What is the best toxicity data to quote to patients for prostate IMRT vs nerve-sparing prostatectomy?

When counseling patients with organ-confined prostate cancer, what rates of impotence, incontinence, rectal toxicity, and urethral stricture shou...

2 Answers available

What is the minimum amount of time you should wait between a TURP and the start of definitive prostate radiation therapy?

2 Answers available

Should prostate cancer genomic classifiers, such as Decipher, be used in all high risk post-prostatectomy patients to risk stratify patients to adjvant RT vs PSA observation and possible salvage RT?

The optimal timing of post-prostatectomy RT in high-risk patients is debatable and currently the question of prospective randomized trials; however, g...

1 Answer available

What is the appropriate treatment for a low lying rectal cancer in the setting of prior definitive prostate IMRT?

Fore example for a T3N0 rectal cancer on EUS?

1 Answer available

What is the best approach to management of newly diagnosed intermediate or high risk prostate cancer in a patient with high grade non-muscle invasive bladder cancer?

In this case, the patient is currently on maintenance BCG.

1 Answer available

Do you feel that HDR brachytherapy alone is adequate treatment for some intermediate-risk prostate cancer patients?

If so, what selection criteria do you use for such patients?

2 Answers available

For which patients with localized prostate cancer is SBRT an alternate standard of care?

1 Answer available

Is there an age that is too young for prostate irradiation?

Do you use a particular cut-off? For example, someone in their 40's?

3 Answers available

Would you treat radio-graphically positive pelvic lymph nodes when palliating a patient with metastatic patient prostate cancer and obstructive symptoms?

The patient has a positive bone scan (2 lesions), grade 4+5=9/10 prostate, and cancer cannot urinate without a catheter.

1 Answer available

Should prophylactic breast radiotherapy still be practiced for patients with prostate cancer taking bicalutamide?

1 Answer available

For intermediate risk prostate cancer do you recommend short-term complete androgen blockade or LHRH agonist alone?

2 Answers available

If one decides to use a mpMRI to stage a pt with low-risk prostate cancer, how do you work up a focal lesion suspicious for higher grade GS 7-10 disease?

1 Answer available

Which patients with intermediate and high risk prostate cancer should not receive androgen deprivation therapy?

More specifically, which cardiac risk factors do you look for? Diabetes? Previous MI? Dyslipidemia? Peripheral vascular disease? CHF?

2 Answers available

For patients with high risk prostate cancer, is there data to support increased morbidity, such as increased urethral strictures or cystitis, when given postprostatectomy XRT as opposed to definitive XRT?

In general how do you counsel patients with high risk prostate cancer when choosing radiation verse prostatectomy? What numbers do you quote for ...

4 Answers available

Would you consider offering salvage radiation to a patient with castrate resistant prostate cancer who has never had local therapy and has no evidence of lymph node or distant metastasis?

This is a patient who would have been an appropriate candidate for radiation upfront, but was managed with androgen deprivation therapy instead. On th...

2 Answers available

If a daily conebeam CT is done for prostate cancer treatments, do you subtract any treatment fractions to compensate for the daily imaging dose?

1 Answer available

What is your technique for CT and MRI fusion for external beam prostate planning?

Sometimes the scans don’t line up well because of differences in rectal and bladder fullness- any tips to optimize the fusion?

1 Answer available

Would you treat a patient who failed cryotherapy?

1 Answer available

For patients with high risk prostate cancer, is there data to support prostatectomy, as opposed to upfront RT?

I ask this because I am seeing more and more patients who have had surgery despite presenting with high risk disease.

1 Answer available

In a low volume prostate cancer (2 of 12 cores, low percentage) with a GS 4+4=8, how long does ADT need to be administered?

1 Answer available

What criteria do you use in deciding whether or not to treat the pelvis in prostate cancer?

I know many do not treat the pelvis at all, but for those who do, what criteria do you use? Risk? Gleason? PSA? T stage?

1 Answer available

What fractionation and dose constraints do you use for prostate SBRT?

1 Answer available

Do you decrease the duration of hormones in a man with high risk prostate cancer and cardiac risk factors?

3 Answers available

What's the safest way to hypofractionate treatment for prostate cancer?

1 Answer available

What is your management strategy for patients with positive lymph nodes after radical prostatectomy?

2 Answers available

Do HIV/AIDS patients with prostate cancer have increased radiation toxicity?

And should special precautions be taken (such as dose reduction, prophylactic symptom management, etc)?

1 Answer available

What is your institution's active surveillance protocol?

1 Answer available

How should I interpret a Gleason 7 prostate cancer (4+3 or 3+4) with tertiary grade 5?

Would you treat this as high risk?

1 Answer available

Is there any data to support the use of hormone therapy with RT in the adjuvant post-prostatectomy setting?

1 Answer available

Papers discussed in this category

International journal of radiation oncology, biology, physics, 2005-04-01

Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31.

Int J Radiat Oncol Biol Phys, 2005 Sep 1

Outcome of salvage radiotherapy for biochemical failure after radical prostatectomy with or without hormonal therapy.

International journal of radiation oncology, biology, physics, 2004-06-01

Radiotherapy after radical prostatectomy: does transient androgen suppression improve outcomes?

International journal of radiation oncology, biology, physics, 2007-08-01

Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience.

International journal of radiation oncology, biology, physics, 2014-04-01

Risk of late toxicity in men receiving dose-escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-11-01

Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer.

Int. J. Radiat. Oncol. Biol. Phys., 2012-12-01

Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer.

European urology, 2013-12

A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy.

CA Cancer J Clin, 2010 May-Jun

Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology.

J Natl Cancer Inst, 2010 Jan 6

Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer.

BJU international, 2014-12

The impact of androgen-deprivation therapy (ADT) on the risk of cardiovascular (CV) events in patients with non-metastatic prostate cancer: a population-based study.

JAMA, 2011-12-07

Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials.

Cancer, 2013 May 15

Death from high-risk prostate cancer versus cardiovascular mortality with hormonal therapy: a decision analysis.

International journal of radiation oncology, biology, physics, 2010-11-01

Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer.

American journal of clinical oncology, 2016-02

Management of Postprostatectomy Biochemical Relapse With Salvage Radiotherapy: Results of an International Survey.

Radiother Oncol, 2013-01-01

Geographical distribution of lymph node metastases on MR lymphography in prostate cancer patients.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010-03-20

Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix.

Eur. Urol., 2009-05-01

Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy.

The American journal of surgical pathology, 2005-09

The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma.

The New England journal of medicine, 2012-07-19

Radical prostatectomy versus observation for localized prostate cancer.

BMJ, 2014-01-08

Prostate cancer: summary of updated NICE guidance.

International journal of radiation oncology, biology, physics, 2012-05-01

Matched cohort analysis of outcomes of definitive radiotherapy for prostate cancer in human immunodeficiency virus-positive patients.

International journal of radiation oncology, biology, physics, 2012-02-01

Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer.

N. Engl. J. Med., 2009-06-11

Duration of androgen suppression in the treatment of prostate cancer.

JAMA, 2006-11-15

Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial.

Practical radiation oncology, 2013

Late toxicity after intensity modulated and image guided radiation therapy for localized prostate cancer and post-prostatectomy patients.

N Engl J Med, 2008 Mar 20

Quality of life and satisfaction with outcome among prostate-cancer survivors.

The Journal of urology, 2011-09

Expanded prostate cancer index composite for clinical practice: development and validation of a practical health related quality of life instrument for use in the routine clinical care of patients with prostate cancer.

Practical radiation oncology, 2013

Intensity modulated radiation therapy after radical prostatectomy: Early results show no decline in urinary continence, gastrointestinal, or sexual quality of life.

Urologic oncology, 2014-04

Optimal timing of early versus delayed adjuvant radiotherapy following radical prostatectomy for locally advanced prostate cancer.

BJU international, 2014-03

A Phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: background and rationale of the Radiotherapy -- Adjuvant Versus Early Salvage (RAVES) trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-03-10

Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy.

J. Urol., 1998-01-01

Adjuvant radiation therapy does not cause urinary incontinence after radical prostatectomy: results of a prospective randomized study.

Eur. Urol., 2014-03-01

Impact of adjuvant radiation therapy on urinary continence recovery after radical prostatectomy.

BJU international, 2015-10

Preoperative predictive model of recovery of urinary continence after radical prostatectomy.

The New England journal of medicine, 2011-07-14

Radiotherapy and short-term androgen deprivation for localized prostate cancer.

International journal of radiation oncology, biology, physics, 2010-04

Total androgen blockade versus a luteinizing hormone-releasing hormone agonist alone in men with high-risk prostate cancer treated with radiotherapy.

JAMA, 2015

Long-term Follow-up of a Randomized Trial of Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008-06-20

Risk of prostate cancer recurrence in men treated with radiation alone or in conjunction with combined or less than combined androgen suppression therapy.

The Journal of urology, 2012-01

High dose brachytherapy as monotherapy for intermediate risk prostate cancer.

Cancers, 2022 Jan 29

Stereotactic Radiotherapy after Radical Prostatectomy in Patients with Prostate Cancer in the Adjuvant or Salvage Setting: A Systematic Review.

International journal of radiation oncology, biology, physics, 2013-03-15

Short-term androgen-deprivation therapy improves prostate cancer-specific mortality in intermediate-risk prostate cancer patients undergoing dose-escalated external beam radiation therapy.

Cancer, 2014-06-15

The likelihood of death from prostate cancer in men with favorable or unfavorable intermediate-risk disease.

Cancer, 2006 Jun 15

Does age matter in the selection of treatment for men with early-stage prostate cancer?

International journal of radiation oncology, biology, physics, 2003-03-15

Effect of age on biochemical disease-free outcome in patients with T1-T3 prostate cancer treated with definitive radiotherapy in an equal-access health care system: a radiation oncology report of the Department of Defense Center for Prostate Disease Research.

Urology, 2008-11

CounterPoint: second malignancies after radiotherapy for prostate cancer: keeping perspective.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004-05-15

Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis.

American journal of clinical oncology, 2014-06

Is there an increase in genitourinary toxicity in patients treated with transurethral resection of the prostate and radiotherapy? A systematic review.

International journal of radiation oncology, biology, physics, 2011-07-15

External beam radiotherapy for prostate cancer: urinary outcomes for men with high International Prostate Symptom Scores (IPSS).

International journal of radiation oncology, biology, physics, 2010-07-15

External beam radiation therapy after transurethral resection of the prostate: a report on acute and late genitourinary toxicity.

Frontiers in oncology, 2011

Six-Dimensional Correction of Intra-Fractional Prostate Motion with CyberKnife Stereotactic Body Radiation Therapy.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999-04

Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-10-20

Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy.

The New England journal of medicine, 2017-02-02

Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer.

JAMA Oncol, 2017-10-01

Imaging Locally Advanced, Recurrent, and Metastatic Prostate Cancer: A Review.

Seminars in radiation oncology, 2013-07

Adjuvant versus salvage radiotherapy for high-risk prostate cancer patients.

Eur Urol, 2015 Jul 16

Progression-free Survival Following Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Treatment-naive Recurrence: A Multi-institutional Analysis.

BJU Int, 2009 Feb

Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial.

European urology, 2014-06

Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007-05-20

Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy.

The New England journal of medicine, 2013-07-18

Alpha emitter radium-223 and survival in metastatic prostate cancer.

JAMA Oncol, 2020 Aug 27

Assessment of Postprostatectomy Radiotherapy as Adjuvant or Salvage Therapy in Patients With Prostate Cancer: A Systematic Review.

Lancet, 2016 Mar 19

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-05-10

Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial.

European urology, 2011-04

The prognostic significance of capsular incision into tumor during radical prostatectomy.

Urology, 2001-11

Does capsular incision at radical retropubic prostatectomy affect disease-free survival in otherwise organ-confined prostate cancer?

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-01-20

Evaluating Intermittent Androgen-Deprivation Therapy Phase III Clinical Trials: The Devil Is in the Details.

J. Nucl. Med., 2015 Jun 25

Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.

Int. J. Radiat. Oncol. Biol. Phys., 2015 Apr 23

Hydrogel Spacer Prospective Multicenter Randomized Controlled Pivotal Trial: Dosimetric and Clinical Effects of Perirectal Spacer Application in Men Undergoing Prostate Image Guided Intensity Modulated Radiation Therapy.

Brachytherapy, 2020 Apr 21

Acute patient-reported bowel quality of life and rectal bleeding with the combination of prostate external beam radiation, low-dose-rate brachytherapy boost, and SpaceOAR.

Int. J. Radiat. Oncol. Biol. Phys., 2020 Jan 24

Derivation of Dose/Volume Constraints for the Anorectum from Clinician- and Patient-Reported Outcomes in the CHHiP Trial of Radiation Therapy Fractionation.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008-04-01

Phase III randomized placebo-controlled trial of two doses of megestrol acetate as treatment for menopausal symptoms in women with breast cancer: Southwest Oncology Group Study 9626.

Lancet Oncol., 2010-02-01

Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006-03-20

Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group Trial N99C7.

The Journal of urology, 2005-08

Parenteral medroxyprogesterone for the management of luteinizing hormone releasing hormone induced hot flashes in men with advanced prostate cancer.

Mol Clin Oncol, 2015 May 04

Bee pollen and honey for the alleviation of hot flushes and other menopausal symptoms in breast cancer patients.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010-12-10

Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-11-10

Randomized trial to assess the impact of venlafaxine and soy protein on hot flashes and quality of life in men with prostate cancer.

The Journal of urology, 1999-07

Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer.

Annals of oncology : official journal of the European Society for Medical Oncology, 2009-03

A phase III randomized, double-blind, placebo-controlled trial of gabapentin in the management of hot flashes in men (N00CB).

Mayo Clin Proc, 2004 Oct

Pilot evaluation of paroxetine for treating hot flashes in men.

JNCI Cancer Spectr, 2019 Oct 21

Oxybutynin vs Placebo for Hot Flashes in Women With or Without Breast Cancer: A Randomized, Double-Blind Clinical Trial (ACCRU SC-1603).

N Engl J Med, 1994 Aug 11

Megestrol acetate for the prevention of hot flashes.

The New England journal of medicine, 2018-05-03

Oxybutynin for Hot Flashes Due to Androgen Deprivation in Men.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002-08-01

Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011-06-20

Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment.

The Journal of urology, 2002-09

Impact of previous local treatment for prostate cancer on subsequent metastatic disease.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2009-01-15

Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence.

Nature, 2005-12-08

VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche.

J Clin Oncol, 1999 Jul

Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: A randomized study.

Lancet, 2015 Jan 3

Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial.

The New England journal of medicine, 2001-12-06

Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.

Lancet, 2001-09-22

Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial.

Breast Cancer Res. Treat., 2010-02-01

Impact of breast surgery on survival in patients with distant metastases at initial presentation: a systematic review of the literature.

The Journal of urology, 1982-06

Treatment of a metastatic prostate derived tumor with surgery and chemotherapy.

Cancer research, 2000-04-15

Irradiation of a primary tumor, unlike surgical removal, enhances angiogenesis suppression at a distal site: potential role of host-tumor interaction.

J. Clin. Oncol., 2009-04-01

Perioperative activation of disseminated tumor cells in bone marrow of patients with prostate cancer.

Oncol. Rep., 2015-12-01

Surgical cytoreduction of the primary tumor reduces metastatic progression in a mouse model of prostate cancer.

Nat Commun, 2015-04-01

Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer.

PLoS ONE, 2016-01-01

Does Radiotherapy for the Primary Tumor Benefit Prostate Cancer Patients with Distant Metastasis at Initial Diagnosis?

J. Urol., 2002-04-01

Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis.

Lancet Oncol., 2015 Sep 09

Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial.

European urology, 2018-02

Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.

Lancet, 2018 Oct 18

Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.

The New England journal of medicine, 2015-08-20

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.

JAMA, 2008-06-18

Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy.

International journal of radiation oncology, biology, physics, 2007-11-01

An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions.

The Lancet. Oncology, 2006-06

Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-06-20

Course and Predictors of Cognitive Function in Patients With Prostate Cancer Receiving Androgen-Deprivation Therapy: A Controlled Comparison.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-02-20

Androgen Deprivation Therapy and Future Alzheimer's Disease Risk.

JAMA oncology, 2016-04

Adverse Health Events Following Intermittent and Continuous Androgen Deprivation in Patients With Metastatic Prostate Cancer.

JAMA oncology, 2017-01-01

Association Between Androgen Deprivation Therapy and Risk of Dementia.

Int J Radiat Oncol Biol Phys, 2012 Jul 15

Treatment outcomes in non-metastatic prostate cancer patients with ultra-high prostate-specific antigen.

International journal of radiation oncology, biology, physics, 2011-06-01

Impact of ultrahigh baseline PSA levels on biochemical and clinical outcomes in two Radiation Therapy Oncology Group prostate clinical trials.

Lancet, 2008 Dec 16

Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.

Lancet, 2011-12-17

Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.

Urology, 2017-04

A Pilot Study of a Multimodal Treatment Paradigm to Accelerate Drug Evaluations in Early-stage Metastatic Prostate Cancer.

Eur Urol Oncol, 2020 May 22

PSMA-PET/CT-based Lymph Node Atlas for Prostate Cancer Patients Recurring After Primary Treatment: Clinical Implications for Salvage Radiation Therapy.

Int J Radiat Oncol Biol Phys, 1986 Mar

Extended field (periaortic) irradiation in carcinoma of the prostate--analysis of RTOG 75-06.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-06-10

External Validation of the Benefit of Adjuvant Radiotherapy for Pathologic N1M0 Prostate Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-12-10

Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer.

JAMA Oncol,

Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial.

J Urol,

Long-term followup of a randomized study of locally advanced prostate cancer treated with combined orchiectomy and external radiotherapy versus radiotherapy alone.

Frontiers in oncology, 2017

Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on 3-Year Toxicity.

International journal of radiation oncology, biology, physics, 2008-09-01

Intrafractional motion of the prostate during hypofractionated radiotherapy.

European urology, 2018-07

Multi-institutional Evaluation of Elective Nodal Irradiation and/or Androgen Deprivation Therapy with Postprostatectomy Salvage Radiotherapy for Prostate Cancer.

International journal of radiation oncology, biology, physics, 2008-04-01

Virtual HDR CyberKnife treatment for localized prostatic carcinoma: dosimetry comparison with HDR brachytherapy and preliminary clinical observations.

International journal of radiation oncology, biology, physics, 2014-07-01

Predictors of rectal tolerance observed in a dose-escalated phase 1-2 trial of stereotactic body radiation therapy for prostate cancer.

International journal of radiation oncology, biology, physics, 2016-07-01

Dose-Escalated Stereotactic Body Radiation Therapy for Patients With Intermediate- and High-Risk Prostate Cancer: Initial Dosimetry Analysis and Patient Outcomes.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2013-11

Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011-05-20

Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer.

Frontiers of radiation therapy and oncology, 2011

Stereotactic body radiotherapy for prostate cancer: current results of a phase II trial.

Semin Radiat Oncol, 2016 Aug 31

Options for Salvage of Radiation Failures for Prostate Cancer.

International journal of radiation oncology, biology, physics, 2018-06-01

Postoperative Radiation Therapy for Prostate Cancer: Comparison of Conventional Versus Hypofractionated Radiation Regimens.

J. Clin. Oncol., 2015 May 26

Impact of Radiotherapy When Added to Androgen-Deprivation Therapy for Locally Advanced Prostate Cancer: Long-Term Quality-of-Life Outcomes From the NCIC CTG PR3/MRC PR07 Randomized Trial.

J. Clin. Oncol.,

Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891.

International journal of radiation oncology, biology, physics, 2012-04-01

High-dose spatially fractionated GRID radiation therapy (SFGRT): a comparison of treatment outcomes with Cerrobend vs. MLC SFGRT.

Brachytherapy, 2016

Salvage external beam radiotherapy for locally recurrent prostate cancer after definitive brachytherapy.

Practical radiation oncology, 2018

Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO, and AUA Evidence-Based Guideline.

Practical radiation oncology, 2018

A multi-institutional phase 2 trial of prostate stereotactic body radiation therapy (SBRT) using continuous real-time evaluation of prostate motion with patient-reported quality of life.

Journal of contemporary brachytherapy, 2016-10

Predictors of prostate volume reduction following neoadjuvant cytoreductive androgen suppression.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-04-10

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial.

International journal of radiation oncology, biology, physics, 2012-07-01

Incidence of secondary cancer development after high-dose intensity-modulated radiotherapy and image-guided brachytherapy for the treatment of localized prostate cancer.

Radiother Oncol, 2009 Apr

Monte Carlo study shows no significant difference in second cancer risk between 6- and 18-MV intensity-modulated radiation therapy.

Lancet, 2021 Dec 23

Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.

Semin Radiat Oncol, 2004-01-01

Errors and margins in radiotherapy.

Practical radiation oncology, 2017

State of dose prescription and compliance to international standard (ICRU-83) in intensity modulated radiation therapy among academic institutions.

The Lancet. Oncology, 2019-03

Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial.

N. Engl. J. Med., 2017-07-27

Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.

Eur. Urol., 2018 Jul 03

Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial.

Lancet, 2019 Apr 11

Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial.

J. Clin. Oncol., 2017 Dec 14

Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial.

Eur. Urol., 2019 Jul 19

Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy.

Ann. Oncol.,

Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005-02-01

Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31.

Urology, 2001-08

Addition of radiation therapy to androgen ablation improves outcome for subclinically node-positive prostate cancer.

BMC Cancer, 2014 Sep 15

Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): study protocol for a randomized phase II trial.

JAMA Oncol,

Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial.

Lancet Oncol., 2016-06-01

Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.

JAMA Oncol, 2020 Mar 26

Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer.

Lancet, 2020 Sep 28

Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial.

Lancet Oncol,

Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial.

Lancet Oncol,

Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial.

The New England journal of medicine, 2017-07-27

Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.

JAMA Oncol, 2021 Feb 18

Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-11-01

ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer.

Radiother Oncol, 2020 Apr 01

Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer.

The Lancet. Oncology, 2012-02

Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials.

International journal of radiation oncology, biology, physics, 2016-11-01

Posttreatment Prostate-Specific Antigen 6 Months After Radiation With Androgen Deprivation Therapy Predicts for Distant Metastasis-Free Survival and Prostate Cancer-Specific Mortality.

Cancer, 2018-07-15

Three-month posttreatment prostate-specific antigen level as a biomarker of treatment response in patients with intermediate-risk or high-risk prostate cancer treated with androgen deprivation therapy and radiotherapy.

Urology, 2000-11-01

Proximity of prostate cancer to the urethra: implications for minimally invasive ablative therapies.

Abdom Radiol (NY), 2019 Aug 29

Apical periurethral transition zone lesions: MRI and histology findings.

Lancet, 2021 May 07

F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial.

N. Engl. J. Med., 2016-10-13

10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer.

J Urol, 2020 Apr 13

Prospective Validation of Gallium-68 Prostate Specific Membrane Antigen-Positron Emission Tomography/Computerized Tomography for Primary Staging of Prostate Cancer. Reply.

Eur J Nucl Med Mol Imaging, 2020 Aug 12

Pelvic lymph-node staging with F-DCFPyL PET/CT prior to extended pelvic lymph-node dissection in primary prostate cancer - the SALT trial.

J Urol,

Outcomes of Primary Lymph Node Staging of Intermediate and High Risk Prostate Cancer with Ga-PSMA Positron Emission Tomography/Computerized Tomography Compared to Histological Correlation of Pelvic Lymph Node Pathology.

Lancet Oncol, 2010 Oct 07

External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-04-10

Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone.

Prostate Cancer Prostatic Dis, 2020 May 13

Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer.

The Lancet. Oncology, 2018-11

Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial.

J Clin Oncol, 2021 Jan 26

Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial.

Pancreas, 2010-08

The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas.

European urology, 2018-08

Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer.

American journal of clinical and experimental urology, 2014

Neuroendocrine differentiation of prostate cancer: a review.

The Prostate. Supplement, 1998

Prognostic significance of neuroendocrine differentiation in clinically localized prostatic carcinoma.

The Prostate, 2001 May 15

Effects of the somatostatin analog lanreotide on the circulating levels of chromogranin-A, prostate-specific antigen, and insulin-like growth factor-1 in advanced prostate cancer patients.

Clinical nuclear medicine, 2017 Jan

PET/CT With 68Ga-DOTA-TATE for Diagnosis of Neuroendocrine: Differentiation in Patients With Castrate-Resistant Prostate Cancer.

The New England journal of medicine, 2018-04-12

Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.

The New England journal of medicine, 2018-06-28

Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.

The New England journal of medicine, 2019-03-28

Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.

Clin Cancer Res, 2019 Sep 11

Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer.

Lancet Oncol, 2019 Oct 16

Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial.

JAMA Oncol,

Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial.

J Urol, 2021 Feb 26

A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with F-DCFPyL in Prostate Cancer Patients (OSPREY).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-02-01

Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910.

International journal of radiation oncology, biology, physics, 2015-06-01

Quantifying Unnecessary Normal Tissue Complication Risks due to Suboptimal Planning: A Secondary Study of RTOG 0126.

International journal of radiation oncology, biology, physics, 2017-06-01

Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology RTOG 9202.

Proceedings of the National Academy of Sciences of the United States of America, 2011-06-07

Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2017-01

68Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience.

European journal of nuclear medicine and molecular imaging, 2018-11

Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer.

European urology oncology, 2018-05

Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer.

J Nucl Med, 2021 Dec 16

Predictors of F-DCFPyL-PET/CT Positivity in Patients with Biochemical Recurrence of Prostate Cancer After Local Therapy.

J Nucl Med, 2018 Dec 14

Rapid Modulation of PSMA Expression by Androgen Deprivation: Serial Ga-PSMA-11 PET in Men with Hormone-Sensitive and Castrate-Resistant Prostate Cancer Commencing Androgen Blockade.

Eur J Nucl Med Mol Imaging, 2019 Nov 15

The effect of androgen deprivation therapy on Ga-PSMA tracer uptake in non-metastatic prostate cancer patients.

Eur J Nucl Med Mol Imaging, 2019 Dec 26

Prospective study on the effect of short-term androgen deprivation therapy on PSMA uptake evaluated with Ga-PSMA-11 PET/MRI in men with treatment-naïve prostate cancer.

JAMA Oncol,

Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging Trial.

J Urol, 2021 Feb 03

The Predictive Value of Preoperative Negative Prostate Specific Membrane Antigen Positron Emission Tomography Imaging for Lymph Node Metastatic Prostate Cancer.

J Nucl Med, 2020 Jan 10

Impact of Ga-PSMA-11 PET/CT on Staging and Management of Prostate Cancer Patients in Various Clinical Settings: A Prospective Single-Center Study.

Clin Cancer Res, 2021 Feb 23

Diagnostic Performance of F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study.

Lancet, 2020 Sep 28

Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data.

BMC cancer, 2019-06-13

A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA).

J Clin Oncol, 2022 Mar 15

Adjuvant Versus Early Salvage Radiation Therapy After Radical Prostatectomy for pN1 Prostate Cancer and the Risk of Death.

Am J Clin Oncol,

Pelvic Reirradiation Utilizing Pulsed Low-dose Rate Radiation Therapy.

Prostate, 2022 Jun 08

The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups.

International journal of radiation oncology, biology, physics, 2006-07-15

Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference.

J Nucl Med, 2021 Jun 24

Lu-Prostate-Specific Membrane Antigen Ligand After Ra Treatment in Men with Bone-Metastatic Castration-Resistant Prostate Cancer: Real-World Clinical Experience.

Oncotarget, 2017 Feb 25

Radioligand therapy of metastatic prostate cancer using Lu-PSMA-617 after radiation exposure to Ra-dichloride.

Practical radiation oncology, 2017

Hydrogel spacer distribution within the perirectal space in patients undergoing radiotherapy for prostate cancer: Impact of spacer symmetry on rectal dose reduction and the clinical consequences of hydrogel infiltration into the rectal wall.

Urologic oncology, 2017-04

An initial negative round of targeted biopsies in men with highly suspicious multiparametric magnetic resonance findings does not exclude clinically significant prostate cancer-Preliminary experience.

Radiology, 2019-03

A Grading System for the Assessment of Risk of Extraprostatic Extension of Prostate Cancer at Multiparametric MRI.

J Clin Oncol, 2014 Dec 15

Long-term follow-up of a large active surveillance cohort of patients with prostate cancer.

BJU Int, 2020 Feb 12

The ProtecT trial: analysis of the patient cohort, baseline risk stratification and disease progression.

JAMA Oncol,

Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate.

BJU Int, 2022 Apr 03

Development and validation of a life expectancy calculator for US patients with prostate cancer.

Int J Radiat Oncol Biol Phys, 2020 Sep 11

Absolute versus Relative Benefit of Androgen Deprivation Therapy for Prostate Cancer: Moving Beyond the Hazard Ratio to Personalize Therapy.

Lancet Oncol, 2022 Jan 17

Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis.

Prostate Int, 2019 Feb 22

The role of prostate-specific antigen density in men with low-risk prostate cancer suitable for active surveillance: results of a prospective observational study.

J Urol, 2019 Sep 06

Prospective Validation of Gallium-68 Prostate Specific Membrane Antigen-Positron Emission Tomography/Computerized Tomography for Primary Staging of Prostate Cancer.

Lancet,

The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial.

AJR Am J Roentgenol, 2022 Jun 29

Head-To-Head Comparison of Ga-PSMA-11 PET/CT and Tc-MDP Bone Scintigraphy for the Detection of Bone Metastases in Patients With Prostate Cancer: A Meta-Analysis.

Eur Radiol, 2022 Aug 08

Validating the screening criteria for bone metastases in treatment-naïve unfavorable intermediate and high-risk prostate cancer - the prevalence and location of bone- and lymph node metastases.

Urology,

Ability of serum prostate-specific antigen levels to predict normal bone scans in patients with newly diagnosed prostate cancer.

Clin Nucl Med,

Comparing 99mTc-PSMA to 99mTc-MDP in Prostate Cancer Staging of the Skeletal System.

Skeletal Radiol, 2014 May 20

Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis.

Eur J Nucl Med Mol Imaging,

The flare phenomenon: still learning after 35 years.

European urology, 2019-09

Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2.

J Clin Oncol, 2021 Jan 20

Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: Results From the FLAME Randomized Phase III Trial.

Radiother Oncol, 2018 May 03

Contouring of prostate tumors on multiparametric MRI: Evaluation of clinical delineations in a multicenter radiotherapy trial.

Int J Radiat Oncol Biol Phys, 2016 Apr 21

Toward Prostate Cancer Contouring Guidelines on Magnetic Resonance Imaging: Dominant Lesion Gross and Clinical Target Volume Coverage Via Accurate Histology Fusion.

AJR Am J Roentgenol, 2020 Sep 02

Prospective Evaluation of PI-RADS Version 2.1 for Prostate Cancer Detection.

Radiology, 2020 Apr 21

Variability of the Positive Predictive Value of PI-RADS for Prostate MRI across 26 Centers: Experience of the Society of Abdominal Radiology Prostate Cancer Disease-focused Panel.

International journal of radiation oncology, biology, physics, 2019-06-01

Ten-Year Outcomes of Moderately Hypofractionated (70 Gy in 28 fractions) Intensity Modulated Radiation Therapy for Localized Prostate Cancer.

Eur Urol, 2021 Apr 03

Impact of Definitive Local Therapy in Men with Primary Small Cell Prostate Carcinoma.

International journal of radiation oncology, biology, physics, 1998-03-01

Ten-year outcomes for pathologic node-positive patients treated in RTOG 75-06.

Front Oncol, 2022 Jun 07

Risk Factors for Biochemical Recurrence After PSMA-PET-Guided Definitive Radiotherapy in Patients With Lymph Node-Positive Prostate Cancer.

Eur Urol, 2022 Jul 27

Re: Pawel Rajwa, Benjamin Pradere, Giorgio Gandaglia, et al. Intensification of Systemic Therapy in Addition to Definitive Local Treatment in Nonmetastatic Unfavourable Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol 2022;82:82-96.

Lancet Oncol,

Considering benefit and risk before routinely recommending SpaceOAR.

Radiother Oncol, 2020 Oct 07

Dose-response with stereotactic body radiotherapy for prostate cancer: A multi-institutional analysis of prostate-specific antigen kinetics and biochemical control.

Int J Radiat Oncol Biol Phys, 2015 Dec 23

Predictive Parameters of Symptomatic Hematochezia Following 5-Fraction Gantry-Based SABR in Prostate Cancer.

Int. J. Radiat. Oncol. Biol. Phys., 2017-06-01

Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer.

Radiother Oncol, 2012 Feb 16

Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer.

AJR Am J Roentgenol, 2021 Jan 21

Diagnostic Accuracy of Ga-PSMA PET/CT for Initial Detection in Patients With Suspected Prostate Cancer: A Systematic Review and Meta-Analysis.

Eur Urol, 2021 Jul 08

OLIGOPELVIS GETUG P07, a Multicenter Phase II Trial of Combined High-dose Salvage Radiotherapy and Hormone Therapy in Oligorecurrent Pelvic Node Relapses in Prostate Cancer.

Eur Urol Focus, 2021 Mar

The Multicenter, Randomized, Phase 2 PEACE V-STORM Trial: Defining the Best Salvage Treatment for Oligorecurrent Nodal Prostate Cancer Metastases.

Adv Radiat Oncol, 2022 Jul 28

Salvage Involved-Field and Extended-Field Radiation Therapy in Positron Emission Tomography-Positive Nodal Recurrent Prostate Cancer: Outcomes and Patterns of Failure.

J Urol, 2019 01

Clinical Usefulness of Total Length of Gleason Pattern 4 on Biopsy in Men with Grade Group 2 Prostate Cancer.

International journal of radiation oncology, biology, physics, 2010-06-01

Incidental testicular irradiation from prostate IMRT: it all adds up.

International journal of radiation oncology, biology, physics, 2012-01-01

Testicular doses in image-guided radiotherapy of prostate cancer.

Urology, 2021 Oct 06

Variation of Serum PSA Levels in COVID-19 Infected Male Patients with Benign Prostatic Hyperplasia (BPH): A Prospective Cohort Studys.

Adv Urol, 2011 Oct 16

Modern Detection of Prostate Cancer's Bone Metastasis: Is the Bone Scan Era Over?

Eur Urol, 2009 Dec 18

When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool.

Practical radiation oncology, 2015

Permanent prostate brachytherapy using high V150.

JAMA, 2005-09-14

Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial.

JAMA oncology, 2018-06-14

Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial.

Int J Radiat Oncol Biol Phys, 2021 Nov 03

Salvage Low-Dose-Rate Prostate Brachytherapy: Clinical Outcomes of a Phase 2 Trial for Local Recurrence after External Beam Radiation Therapy (NRG Oncology/RTOG 0526).

Eur Urol, 2021 Dec 23

Patterns of Failure Following External Beam Radiotherapy With or Without an Additional Focal Boost in the Randomized Controlled FLAME Trial for Localized Prostate Cancer.

Int J Radiat Oncol Biol Phys, 2000 Sep 01

Postradiotherapy prostate biopsies: what do they really mean? Results for 498 patients.

Radiother Oncol, 2021 Feb 13

Predictors for post-treatment biopsy outcomes after prostate stereotactic body radiotherapy.

J Clin Oncol, 2023 Apr 27

Dose-Escalated Radiotherapy Alone or in Combination With Short-Term Androgen Deprivation for Intermediate-Risk Prostate Cancer: Results of a Phase III Multi-Institutional Trial.

Front Oncol, 2022 Mar 29

Urethra Sparing With Target Motion Mitigation in Dose-Escalated Extreme Hypofractionated Prostate Cancer Radiotherapy: 7-Year Results From a Phase II Study.

Brachytherapy, 2022 May 04

Detection of failure patterns using advanced imaging in patients with biochemical recurrence following low-dose-rate brachytherapy for prostate cancer.

Pract Radiat Oncol, 2023 Jul 11

A Phase I Trial of Focal Salvage Stereotactic Body Radiation Therapy for Radiorecurrent Prostate Cancer.

Pract Radiat Oncol, 2021 May 30

Salvage High-Dose-Rate Brachytherapy for Recurrent Prostate Cancer After Definitive Radiation.

Scandinavian journal of urology and nephrology, 2004

Does brachytherapy of the prostate affect sperm quality and/or fertility in younger men?

BJU international, 2005-10

New life after prostate brachytherapy? Considering the fertile female partner of the brachytherapy patient.

Andrologia, 2017-02

Successful sperm extraction and live birth after radiation, androgen deprivation and surgical castration for treatment of metastatic prostate cancer.

Current opinion in urology, 2007 Nov

Therapeutic testis biopsy for sperm retrieval.

N Engl J Med, 2021 Jun 23

Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.

Lancet, 2019 Jun 18

Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.

Int J Radiat Oncol Biol Phys, 2015 Jul 15

A Phase 1/2 Trial of Brief Androgen Suppression and Stereotactic Radiation Therapy (FASTR) for High-Risk Prostate Cancer.

J Clin Oncol, 2019 Dec 12

Sequencing of Androgen-Deprivation Therapy With External-Beam Radiotherapy in Localized Prostate Cancer: A Phase III Randomized Controlled Trial.

J Clin Oncol, 2021 Jan 10

Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis-Free Survival Compared to Neoadjuvant ADT: An Individual Patient Meta-Analysis.

J. Clin. Oncol., 2016-05-20

Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991.

Lancet Oncol., 2018 Dec 19

Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.

Lancet Oncol, 2015 Feb 19

High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.

Eur J Cancer, 2020 Dec 03

Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: A randomised phase III trial.

Pract Radiat Oncol, 2022 Mar-Apr

Feasibility of Same-Day Prostate Fiducial Markers, Perirectal Hydrogel Spacer Placement, and Computed Tomography and Magnetic Resonance Imaging Simulation for External Beam Radiation Therapy for Low-Risk and Intermediate-Risk Prostate Cancer.

Prostate, 2020 Feb

Correlation between cribriform/intraductal prostatic adenocarcinoma and percent Gleason pattern 4 to a 22-gene genomic classifier.

BJUI Compass, 2021 Jan 05

Ductal adenocarcinoma of the prostate: A systematic review and meta-analysis of incidence, presentation, prognosis, and management.

Lancet, 2022 Apr 08

Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.

Eur Urol, 2018 Sep 25

Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial.

Eur Urol, 2015 May 21

Treatment of the Primary Tumor in Metastatic Prostate Cancer: Current Concepts and Future Perspectives.

JAMA oncology, 2023 Jun 01

Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical Trial.

International journal of radiation oncology, biology, physics, 2019-08-01

Prostate-Specific Antigen After Neoadjuvant Androgen Suppression in Prostate Cancer Patients Receiving Short-Term Androgen Suppression and External Beam Radiation Therapy: Pooled Analysis of Four NRG Oncology Radiation Therapy Oncology Group Randomized Clinical Trials.

Lancet, 2021 Feb 11

[Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.

Eur J Nucl Med Mol Imaging, 2023 Jul 05

The significance of metabolic response to neoadjuvant androgen deprivation therapy detected with [Ga]Ga-PSMA-11-PET/CT in high-risk prostate cancer patients treated with definitive radiotherapy.

BJU Int, 2021 Dec 13

The clinical characteristics of patients with primary non-prostate-specific membrane antigen-expressing prostate cancer on preoperative positron emission tomography/computed tomography.

J Urol, 2021 Jan 27

Outcomes of Post-Neoadjuvant Intense Hormone Therapy and Surgery for High Risk Localized Prostate Cancer: Results of a Pooled Analysis of Contemporary Clinical Trials.

Eur Urol, 2020 Jan 08

Veterans Affairs Cooperative Studies Program Study #553: Chemotherapy After Prostatectomy for High-risk Prostate Carcinoma: A Phase III Randomized Study.

Int J Radiat Oncol Biol Phys, 2019 Oct 10

Spinal Cord Dose Tolerance to Stereotactic Body Radiation Therapy.

EJNMMI physics, 2023 Feb 09

Investigation of image-based lesion and kidney dosimetry protocols for Lu-PSMA-I&T therapy with and without a late SPECT/CT acquisition.

Lancet Oncol, 2019 Sep 17

Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.

Lancet Oncol, 2021 Feb

Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial.

The Lancet. Oncology, 2022 Sep 13

Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial.

Radiother Oncol, 2018 Jan 11

Standard whole prostate gland radiotherapy with and without lesion boost in prostate cancer: Toxicity in the FLAME randomized controlled trial.

Brachytherapy, 2022 Apr 06

Brachytherapy focal dose escalation using ultrasound based tissue characterization by patients with non-metastatic prostate cancer: Five-year results from single-center phase 2 trial.

International journal of radiation oncology, biology, physics, 2022 Dec 15

An Updated Analysis of the Survival Endpoints of ASCENDE-RT.

The Lancet. Oncology, 2014-05

Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study.

The New England journal of medicine, 2023 Oct 19

Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer.

Health and quality of life outcomes, 2020 May 12

How is the minimal clinically important difference established in health-related quality of life instruments? Review of anchors and methods.

European urology, 2015 Feb 14

Long-term Efficacy and Safety of Enzalutamide Monotherapy in Hormone-naïve Prostate Cancer: 1- and 2-Year Open-label Follow-up Results.

International journal of cancer, 2022 May 16

Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476).

Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2022 Oct 27

Safety and Survival Outcomes of Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior Ra treatment: The RALU Study.

European urology, 2022 Apr 18

Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021.

The New England journal of medicine, 2018-05-10

MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis.

The New England journal of medicine, 2020 Mar 05

MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis.

JAMA oncology, 2023 Mar 01

Magnetic Resonance Imaging-Guided vs Computed Tomography-Guided Stereotactic Body Radiotherapy for Prostate Cancer: The MIRAGE Randomized Clinical Trial.

Int J Radiat Oncol Biol Phys, 2019 Oct 17

Retreatment for Local Recurrence of Prostatic Carcinoma After Prior Therapeutic Irradiation: Efficacy and Toxicity of HDR-Like SBRT.

International journal of radiation oncology, biology, physics, 2024 Feb 28

A Phase I Trial of Salvage Stereotactic Body Radiation Therapy for Radiorecurrent Prostate Cancer After Brachytherapy.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2020 Jan 10

Management of Patients with Renal Failure Undergoing Dialysis During I Therapy for Thyroid Cancer.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2023 Jun 08

SNMMI Consensus Statement on Patient Selection and Appropriate Use of Lu-PSMA-617 Radionuclide Therapy.

Radiation Oncology

Prostate Cancer

Questions discussed in this category

Papers discussed in this category

Related Topics in Radiation Oncology